Neurologix needs partner or funds to move Parkinson's gene therapy towards Phase III
This article was originally published in Scrip
Executive Summary
Neurologix is planning to submit a Phase III trial design under a special protocol assessment (SPA) to the US FDA later this year for NLX-P101, its glutamic acid decarboxylase gene therapy for Parkinson's disease, having discussed the product's recently-obtained Phase II data with the agency. However, given that its current finances will take it only through until the end of this year, the company's success or otherwise in raising support for the trial will test just how committed investors or large companies are to gene therapeutics.